CLD Foundation | WebCast Events


	Emerging Concepts in Diagnosis and Management of Hepatic Encephalopathy: Past, Present, and Future
	Dear Physician: The diagnosis and management of hepatic encephalopathy (HE), a common neuropsychiatric disorder that occurs in patients with acute liver failure and advanced chronic liver disease, represents a significant challenge for clinician. In its mildest forms, referred to as minimal HE, the cognitive and motor manifestations are associated with various degrees of impaired social and occupational function, while the more severe forms of the disease are associated with rapid deterioration of consciousness level, potentially progressing to coma and death. Recent improvements have been made in our understanding of the pathogenesis, diagnosis, and treatment of HE, leading to the development of a comprehensive algorithm that will help clinicians identify the different forms of HE and select the appropriate treatment. It is our pleasure to welcome you to this satellite symposium webcast entitled Emerging Concepts in Diagnosis and Management of Hepatic Encephalopathy: Past, Present, and Future. This activity will provide an interactive forum to evaluate case-based issues and advances in the classification of HE. The faculty will also discuss overcoming barriers in the diagnosis of HE and strategies for the management of HE using a newly developed algorithm. Additionally, you will hear about a mortality and pharmacoeconomic analysis of currently used therapies. This activity has been accredited for 2 AMA PRA Category 1 Credits™. Sincerely, Chronic Liver Disease Foundation
	Chairperson Kevin D. Mullen, MD Professor of Medicine Case Western Reserve University MetroHealth Medical Center Cleveland, OH Faculty Peter Ferenci, MD Professor of Medicine Medical University of Vienna Vienna, Austria Guy W. Neff, MD, MBA Associate Professor of Medicine Medical Director, Hepatic Transplantation University of Cincinnati Cincinnati, Ohio CME Reviewer Adnan Said, MD Assistant Professor of Medicine University of Wisconsin School of Medicine and Public Health Madison, Wisconsin Release - February 29, 2008 Expiration - February 28, 2009 Program Description Hepatic Encephalopathy (HE) is a serious and progressive but potentially reversible neuropsychiatric disorder caused by the accumulation of toxins in the blood of patients with acute liver failure and chronic liver disease. The diagnosis of HE is frequently complicated by he variability of the disorder and the presence of concomitant precipitating factors. The goals of treatment are to reverse acute episodes, prevent further episodes, improve minimal HE, and improve persistent HE. The resulting economic burden of treating HE is dependent on the severity of the condition and the specific treatments used. This interactive program is designed to educate practicing physicians on the clinical challenges they may encounter in the diagnosis and management of HE. Target Audience This educational resource has been designed to meet the needs of gastroenterologists, hepatologists, and other healthcare professionals who diagnose and treat patients with HE. Goal Statement To provide important clinical data on the management of HE. Educational Objectives At the conclusion of this activity, participants should be able to: Build awareness among clinicians regarding minimal and early-stage overt HE, including the poor quality of life associated with these forms of HE and the need for accurate diagnosis Explain the methods and grading systems available for the diagnosis of minimal and early-stage overt HE Discuss issues with current methods for the diagnosis of minimal HE and review data on emerging methods that are currently under clinical evaluation Review the clinical experience to date with conventional and emerging therapeutic approaches Review an evidence-based treatment algorithm for the management of minimal and overt HE Accreditation Statement This activity as been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Wisconsin School of Medicine and Public Health and the Chronic Liver Disease Foundation. The University of Wisconsin School of Medicine and Public Health is accredited by the ACCME to provide continuing medical education for physicians. Credit Designation The University of Wisconsin School of Medicine and Public Health designates this educational activity for a maximum of 2 AMA PRA Category 1 Credits™ Physicians should only claim credit commensurate with the extent of their participation in the activity. Policy on Faculty and Sponsor Disclosure It is the policy of the University of Wisconsin School of Medicine and Public Health that the faculty and sponsor disclose real or apparent conflicts of interest relating to the topics of this education activity and also disclose discussions of unlabeled/unapproved use of drugs or devices during their presentation(s). Detailed disclosure information found below. Disclosures The joint sponsor and faculty have disclosed the following: Peter Ferenci, MD - Has received honoraria from F. Hoffmann-La Roche Ltd and Merz Pharma - Has acted as a speaker for F. Hoffman-La Roche Ltd and Merz Pharma - Has been a member of the Advisory Board of F. Hoffmann-La Roce Ltd Kevin D. Mullen, MD - Has received honoraria and acted as a speaker for Salix Pharmaceuticals, Inc. Guy Neff, MD - Has no financial relationships to disclose Adnan Said, MD - Has no financial relationships to disclose Acknowledgment The University of Wisconsin School of Medicine and Public Health and the Chronic Liver Disease Foundation gratefully acknowledge the independent educational grant provided by Salix Pharmaceuticals, Inc.

	Launch Program Obtain CME Credits
	*Jointly sponsored by:*		*Supported by:*